China Resources Pharmaceutical subsidiary Tasly Pharmaceutical’s nine-month net profit rises to RMB 1.09 billion

• Tasly Pharmaceutical, a China Resources Pharmaceutical subsidiary, released unaudited results for the nine months ended September 30, 2026, on October 23.
• Net profit rose to RMB 1.09 billion from RMB 992.55 million a year earlier.
• Revenue fell to RMB 6.07 billion from RMB 6.31 billion a year earlier.
• Cash and cash equivalents decreased by RMB 478.41 million, versus an increase of RMB 365.73 million a year earlier.
• Period-end cash and cash equivalents totaled RMB 936.67 million, down from RMB 1.18 billion a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12381521), on October 23, 2026, and is solely responsible for the information contained therein.